Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aronora has big plans for its cardiovascular drugs The Contact Activation System as a Potential Therapeutic Target in Patients with COVID‐19 The protein C activator AB002 rapidly interrupts thrombus development in baboons.Aronora is a translational biotechnology company (aronorabio.com) engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monolconal antibodies and en...
Aronora has big plans for its cardiovascular drugs The Contact Activation System as a Potential Therapeutic Target in Patients with COVID‐19 The protein C activator AB002 rapidly interrupts thrombus development in baboons.Aronora is a translational biotechnology company (aronorabio.com) engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. Rational design of our innovative therapeutic agents is expected to result in drug products that reduce the progression and growth of life-threatening blood clots

List your booth number for exhibitions, ask us